MESO vs. IMTX, RLAY, RGNX, CRGX, AUTL, BCRX, HLVX, PRME, NVAX, and SRRK
Should you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Immatics (IMTX), Relay Therapeutics (RLAY), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Autolus Therapeutics (AUTL), BioCryst Pharmaceuticals (BCRX), HilleVax (HLVX), Prime Medicine (PRME), Novavax (NVAX), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.
Immatics (NASDAQ:IMTX) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.
Immatics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.45, suggesting that its share price is 245% more volatile than the S&P 500.
64.4% of Immatics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Mesoblast has a net margin of 0.00% compared to Mesoblast's net margin of -107.80%. Immatics' return on equity of 0.00% beat Mesoblast's return on equity.
Immatics currently has a consensus target price of $16.00, suggesting a potential upside of 49.11%. Mesoblast has a consensus target price of $13.67, suggesting a potential upside of 84.93%. Given Immatics' higher probable upside, analysts clearly believe Mesoblast is more favorable than Immatics.
Mesoblast received 377 more outperform votes than Immatics when rated by MarketBeat users. However, 72.22% of users gave Immatics an outperform vote while only 70.45% of users gave Mesoblast an outperform vote.
In the previous week, Immatics had 13 more articles in the media than Mesoblast. MarketBeat recorded 16 mentions for Immatics and 3 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.69 beat Immatics' score of 0.48 indicating that Immatics is being referred to more favorably in the media.
Mesoblast has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.
Summary
Mesoblast beats Immatics on 10 of the 17 factors compared between the two stocks.
Get Mesoblast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mesoblast Competitors List
Related Companies and Tools
